Research ArticleArticle
Open Access
Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
Yoshiya Tanaka, Kahaku Emoto, Zhihong Cai, Takehiro Aoki, Douglas Schlichting, Terence Rooney and William Macias
The Journal of Rheumatology February 2016, jrheum.150613; DOI: https://doi.org/10.3899/jrheum.150613
Yoshiya Tanaka
From the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Eli Lilly and Co., Tokyo; Eli Lilly Japan K.K., Kobe, Japan; Eli Lilly and Co., Indianapolis, Indiana, USA. Sponsored by Eli Lilly Japan K.K. and Eli Lilly and Co., manufacturer/licensee of baricitinib. Eli Lilly Japan K.K. and Eli Lilly and Co. were involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Janelle Keys, PhD, CMPP, and Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group, and was funded by Eli Lilly Japan K.K. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP2). ZC and TA are employees of Eli Lilly Japan K.K. KE, DS, TR, and WM are employees of Eli Lilly and Co. and KE owns stock in the company. Y. Tanaka, MD, PhD, Professor, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; K. Emoto, MD, PhD, Medical Advisor, Eli Lilly and Co.; Z. Cai, PhD, Senior Associate, Eli Lilly Japan K.K.; T. Aoki, PhD, Senior Associate, Eli Lilly Japan K.K.; D. Schlichting, RN, MS, Principal Research Scientist, Eli Lilly and Co.; T. Rooney, MD, Medical Director, Eli Lilly and Co.; W. Macias, MD, PhD, Distinguished Medical Fellow, Eli Lilly and Co. Address correspondence to Dr. K. Emoto, Eli Lilly and Co., Akasaka, Minato-ku, Tokyo, 107-0052, Japan. E-mail: emoto_kahaku@lilly.com Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 13, 2015.
Kahaku Emoto
From the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Eli Lilly and Co., Tokyo; Eli Lilly Japan K.K., Kobe, Japan; Eli Lilly and Co., Indianapolis, Indiana, USA. Sponsored by Eli Lilly Japan K.K. and Eli Lilly and Co., manufacturer/licensee of baricitinib. Eli Lilly Japan K.K. and Eli Lilly and Co. were involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Janelle Keys, PhD, CMPP, and Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group, and was funded by Eli Lilly Japan K.K. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP2). ZC and TA are employees of Eli Lilly Japan K.K. KE, DS, TR, and WM are employees of Eli Lilly and Co. and KE owns stock in the company. Y. Tanaka, MD, PhD, Professor, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; K. Emoto, MD, PhD, Medical Advisor, Eli Lilly and Co.; Z. Cai, PhD, Senior Associate, Eli Lilly Japan K.K.; T. Aoki, PhD, Senior Associate, Eli Lilly Japan K.K.; D. Schlichting, RN, MS, Principal Research Scientist, Eli Lilly and Co.; T. Rooney, MD, Medical Director, Eli Lilly and Co.; W. Macias, MD, PhD, Distinguished Medical Fellow, Eli Lilly and Co. Address correspondence to Dr. K. Emoto, Eli Lilly and Co., Akasaka, Minato-ku, Tokyo, 107-0052, Japan. E-mail: emoto_kahaku@lilly.com Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 13, 2015.
Zhihong Cai
From the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Eli Lilly and Co., Tokyo; Eli Lilly Japan K.K., Kobe, Japan; Eli Lilly and Co., Indianapolis, Indiana, USA. Sponsored by Eli Lilly Japan K.K. and Eli Lilly and Co., manufacturer/licensee of baricitinib. Eli Lilly Japan K.K. and Eli Lilly and Co. were involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Janelle Keys, PhD, CMPP, and Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group, and was funded by Eli Lilly Japan K.K. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP2). ZC and TA are employees of Eli Lilly Japan K.K. KE, DS, TR, and WM are employees of Eli Lilly and Co. and KE owns stock in the company. Y. Tanaka, MD, PhD, Professor, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; K. Emoto, MD, PhD, Medical Advisor, Eli Lilly and Co.; Z. Cai, PhD, Senior Associate, Eli Lilly Japan K.K.; T. Aoki, PhD, Senior Associate, Eli Lilly Japan K.K.; D. Schlichting, RN, MS, Principal Research Scientist, Eli Lilly and Co.; T. Rooney, MD, Medical Director, Eli Lilly and Co.; W. Macias, MD, PhD, Distinguished Medical Fellow, Eli Lilly and Co. Address correspondence to Dr. K. Emoto, Eli Lilly and Co., Akasaka, Minato-ku, Tokyo, 107-0052, Japan. E-mail: emoto_kahaku@lilly.com Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 13, 2015.
Takehiro Aoki
From the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Eli Lilly and Co., Tokyo; Eli Lilly Japan K.K., Kobe, Japan; Eli Lilly and Co., Indianapolis, Indiana, USA. Sponsored by Eli Lilly Japan K.K. and Eli Lilly and Co., manufacturer/licensee of baricitinib. Eli Lilly Japan K.K. and Eli Lilly and Co. were involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Janelle Keys, PhD, CMPP, and Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group, and was funded by Eli Lilly Japan K.K. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP2). ZC and TA are employees of Eli Lilly Japan K.K. KE, DS, TR, and WM are employees of Eli Lilly and Co. and KE owns stock in the company. Y. Tanaka, MD, PhD, Professor, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; K. Emoto, MD, PhD, Medical Advisor, Eli Lilly and Co.; Z. Cai, PhD, Senior Associate, Eli Lilly Japan K.K.; T. Aoki, PhD, Senior Associate, Eli Lilly Japan K.K.; D. Schlichting, RN, MS, Principal Research Scientist, Eli Lilly and Co.; T. Rooney, MD, Medical Director, Eli Lilly and Co.; W. Macias, MD, PhD, Distinguished Medical Fellow, Eli Lilly and Co. Address correspondence to Dr. K. Emoto, Eli Lilly and Co., Akasaka, Minato-ku, Tokyo, 107-0052, Japan. E-mail: emoto_kahaku@lilly.com Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 13, 2015.
Douglas Schlichting
From the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Eli Lilly and Co., Tokyo; Eli Lilly Japan K.K., Kobe, Japan; Eli Lilly and Co., Indianapolis, Indiana, USA. Sponsored by Eli Lilly Japan K.K. and Eli Lilly and Co., manufacturer/licensee of baricitinib. Eli Lilly Japan K.K. and Eli Lilly and Co. were involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Janelle Keys, PhD, CMPP, and Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group, and was funded by Eli Lilly Japan K.K. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP2). ZC and TA are employees of Eli Lilly Japan K.K. KE, DS, TR, and WM are employees of Eli Lilly and Co. and KE owns stock in the company. Y. Tanaka, MD, PhD, Professor, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; K. Emoto, MD, PhD, Medical Advisor, Eli Lilly and Co.; Z. Cai, PhD, Senior Associate, Eli Lilly Japan K.K.; T. Aoki, PhD, Senior Associate, Eli Lilly Japan K.K.; D. Schlichting, RN, MS, Principal Research Scientist, Eli Lilly and Co.; T. Rooney, MD, Medical Director, Eli Lilly and Co.; W. Macias, MD, PhD, Distinguished Medical Fellow, Eli Lilly and Co. Address correspondence to Dr. K. Emoto, Eli Lilly and Co., Akasaka, Minato-ku, Tokyo, 107-0052, Japan. E-mail: emoto_kahaku@lilly.com Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 13, 2015.
Terence Rooney
From the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Eli Lilly and Co., Tokyo; Eli Lilly Japan K.K., Kobe, Japan; Eli Lilly and Co., Indianapolis, Indiana, USA. Sponsored by Eli Lilly Japan K.K. and Eli Lilly and Co., manufacturer/licensee of baricitinib. Eli Lilly Japan K.K. and Eli Lilly and Co. were involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Janelle Keys, PhD, CMPP, and Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group, and was funded by Eli Lilly Japan K.K. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP2). ZC and TA are employees of Eli Lilly Japan K.K. KE, DS, TR, and WM are employees of Eli Lilly and Co. and KE owns stock in the company. Y. Tanaka, MD, PhD, Professor, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; K. Emoto, MD, PhD, Medical Advisor, Eli Lilly and Co.; Z. Cai, PhD, Senior Associate, Eli Lilly Japan K.K.; T. Aoki, PhD, Senior Associate, Eli Lilly Japan K.K.; D. Schlichting, RN, MS, Principal Research Scientist, Eli Lilly and Co.; T. Rooney, MD, Medical Director, Eli Lilly and Co.; W. Macias, MD, PhD, Distinguished Medical Fellow, Eli Lilly and Co. Address correspondence to Dr. K. Emoto, Eli Lilly and Co., Akasaka, Minato-ku, Tokyo, 107-0052, Japan. E-mail: emoto_kahaku@lilly.com Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 13, 2015.
William Macias
From the First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu; Eli Lilly and Co., Tokyo; Eli Lilly Japan K.K., Kobe, Japan; Eli Lilly and Co., Indianapolis, Indiana, USA. Sponsored by Eli Lilly Japan K.K. and Eli Lilly and Co., manufacturer/licensee of baricitinib. Eli Lilly Japan K.K. and Eli Lilly and Co. were involved in the study design, data collection, data analysis, and preparation of the manuscript. Medical writing assistance was provided by Janelle Keys, PhD, CMPP, and Rebecca Lew, PhD, CMPP, of ProScribe, part of the Envision Pharma Group, and was funded by Eli Lilly Japan K.K. ProScribe’s services complied with international guidelines for Good Publication Practice (GPP2). ZC and TA are employees of Eli Lilly Japan K.K. KE, DS, TR, and WM are employees of Eli Lilly and Co. and KE owns stock in the company. Y. Tanaka, MD, PhD, Professor, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health; K. Emoto, MD, PhD, Medical Advisor, Eli Lilly and Co.; Z. Cai, PhD, Senior Associate, Eli Lilly Japan K.K.; T. Aoki, PhD, Senior Associate, Eli Lilly Japan K.K.; D. Schlichting, RN, MS, Principal Research Scientist, Eli Lilly and Co.; T. Rooney, MD, Medical Director, Eli Lilly and Co.; W. Macias, MD, PhD, Distinguished Medical Fellow, Eli Lilly and Co. Address correspondence to Dr. K. Emoto, Eli Lilly and Co., Akasaka, Minato-ku, Tokyo, 107-0052, Japan. E-mail: emoto_kahaku@lilly.com Full Release Article. For details see Reprints/Permissions at jrheum.org. Accepted for publication November 13, 2015.
Article Figures & Data
Additional Files
Data Supplement
Data Supplement
Files in this Data Supplement:
- Data Supplement - Data Supplement
Supplementary Information
Supplementary Information
Files in this Data Supplement:
- Supplementary Information - Supplementary Information
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
Yoshiya Tanaka, Kahaku Emoto, Zhihong Cai, Takehiro Aoki, Douglas Schlichting, Terence Rooney, William Macias
The Journal of Rheumatology Feb 2016, jrheum.150613; DOI: 10.3899/jrheum.150613
Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study
Yoshiya Tanaka, Kahaku Emoto, Zhihong Cai, Takehiro Aoki, Douglas Schlichting, Terence Rooney, William Macias
The Journal of Rheumatology Feb 2016, jrheum.150613; DOI: 10.3899/jrheum.150613